1Wormser, U (1991) Toxicology of mustard gas. Trends Pharmacol Sci 12, 164–167.
2Kehe, K & Szinicz, L (2005) Medical aspects of sulphur mustard poisoning. Toxicology 214, 198–209.
3Khateri, S, Ghanei, M, Keshavarz, S, et al. (2003) Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 45, 1136–1143.
4United Nations Security Council (1986) Reports of the Specialists Appointed by the Secretary General to Investigate Allegations by the Islamic Republic of Iran Concerning the Use of Chemical Weapons. . New York, NY: Security Council of the United Nations.
5Balali-Mood, M & Hefazi, M (2005) The clinical toxicology of sulfur mustard. Arch Iranian Med 8, 162–179.
6Shohrati, M, Peyman, M, Peyman, A, et al. (2007) Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan Ocul Toxicol 26, 73–81.
7Panahi, Y, Davoudi, SM, Sadr, SB, et al. (2008) Impact of pruritus on quality of life in sulfur mustard-exposed Iranian veterans. Int J Dermatol 47, 557–561.
8Weisshaar, E & Diepgen, TL (2005) Pruritus and quality of life. J Invest Dermatol 125, 855–855.
9Weisshaar, E, Apfelbracher, C, Jager, G, et al. (2006) Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 155, 957–964.
10Ghabili, K, Agutter, PS, Ghanei, M, et al. (2011) Sulfur mustard toxicity: history, chemistry, pharmacokinetics, and pharmacodynamics. Crit Rev Toxicol 41, 384–403.
11Naghii, MR (2002) Sulfur mustard intoxication, oxidative stress, and antioxidants. Mil Med 167, 573–575.
12Thomsen, JS, Sonne, M, Benfeldt, E, et al. (2002) Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br J Dermatol 146, 792–800.
13Hägermark, O, Hökfelt, T & Pernow, B (1978) Flare and itch induced by substance P in human skin. J Invest Dermatol 71, 233–235.
14Lotz, M, Vaughan, JH & Carson, DA (1988) Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241, 1218–1221.
15Lieb, K, Fiebich, BL, Berger, M, et al. (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159, 4952–4958.
16Panahi, Y, Davoodi, SM, Khalili, H, et al. (2007) Phenol and menthol in the treatment of chronic skin lesions following mustard gas exposure. Singapore Med J 48, 392–395.
17Panahi, Y, Moharamzad, Y, Beiraghdar, F, et al. (2009) Comparison of clinical efficacy of topical pimecrolimus with betamethasone in chronic skin lesions due to sulfur mustard exposure: a randomized, investigator-blind study. Basic Clin Pharmacol Toxicol 104, 171–175.
18Panahi, Y, Davoudi, SM, Moharamzad, Y, et al. (2008) Comparison of topical capsaicin and betamethasone in the treatment of chronic skin lesions due to sulfur mustard exposure. Cutan Ocul Toxicol 27, 203–211.
19Shohrati, M, Davoudi, M, Almasi, M, et al. (2007) Comparative study of Unna's Boot and betamethasone cream in the treatment of sulfur mustard-related pruritus. Cutan Ocul Toxicol 26, 303–309.
20Shohrati, M, Davoudi, SM, Keshavarz, S, et al. (2007) Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol 26, 249–255.
21Henqque, UR, Ruzicka, T, Schwartz, RA, et al. (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54, 1–15.
22Pari, L, Tewas, D & Eckel, J (2008) Role of curcumin in health and disease. Arch Physiol Biochem 114, 127–149.
23Goel, A, Kunnumakkara, AB & Aggarwal, BB (2008) Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75, 787–809.
24Epstein, J, Sanderson, IR & Macdonald, TT (2010) Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103, 1545–1557.
25Paromov, V, Suntres, Z, Smith, M, et al. (2007) Sulfur mustard toxicity following dermal exposure: role of oxidative stress, and antioxidant therapy. J Burns Wounds 7, e7.
26Shoba, G, Joy, D, Joseph, T, et al. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64, 353–356.
27Rickham, PP (1964) Human experimentation. code of ethics of the world medical association. Declaration of Helsinki. Br Med J 2, 177.
28Balaskas, EV, Bamihas, GI, Karamouzis, M, et al. (1998) Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 78, 395–402.
29European Task Force on Atopic Dermatitis (1993) Severity scoring of atopic dermatitis: the SCORAD Index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 186, 23–31.
30Aggarwal, BB, Kumar, A & Bharti, AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23, 363–398.
31Chainani-Wu, N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9, 161–168.
32Thangapazham, RL, Sharma, A & Maheshwari, RK (2007) Beneficial role of curcumin in skin diseases. Adv Exp Med Biol 595, 343–357.
33Sikora, E, Scapagnini, G & Barbagallo, M (2010) Curcumin, inflammation, ageing and age-related diseases. Immun Ageing 7, 1.
34Shakarjian, MP, Heck, DE, Gray, JP, et al. (2010) Mechanisms mediating the vesicant actions of sulfur mustard after cutaneous exposure. Toxicol Sci 114, 5–19.
35Jin, CY, Lee, JD, Park, C, et al. (2007) Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. Acta Pharmacol Sin 28, 1645–1651.
36Abe, Y, Hashimoto, S & Horie, T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39, 41–47.
37Jurenka, JS (2009) Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14, 141–153.
38Brimfield, A, Mancebo, A, Mason, R, et al. (2009) Free radical production from the interaction of 2-chloroethyl vesicants (mustard gas) with pyridine nucleotide-driven flavoprotein electron transport systems. Toxicol Appl Pharmacol 234, 128–134.
39Jafari, M & Ghanei, M (2010) Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fluid antioxidant defense system in sulfur mustard-injured patients. Clin Toxicol (Phila) 48, 184–192.
40Eldad, A, Ben Meir, P, Breiterman, S, et al. (1998) Superoxide dismutase (SOD) for mustard gas burns. Burns 24, 114–119.
41Gross, CL, Nealley, EW, Nipwoda, MT, et al. (2006) Pretreatment of human epidermal keratinocytes with dl-sulforaphane protects against sulfur mustard cytotoxicity. Cutan Ocul Toxicol 25, 155–163.
42Calabrese, V, Bates, TE, Mancuso, C, et al. (2008) Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res 52, 1062–1073.
43Menon, VP & Sudheer, AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595, 105–125.
44Bengmark, S (2006) Curcumin, an atoxic antioxidant and natural NFκB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr 30, 45–51.
45Ragunathan, I & Panneerselvam, N (2007) Antimutagenic potential of curcumin on chromosomal aberrations in Allium cepa. J Zhejiang Univ Sci B 8, 470–475.
46de Craen, AJ, Kaptchuk, TJ, Tijssen, JG, et al. (1999) Placebos and placebo effects in medicine: historical overview. J R Soc Med 92, 511–515.
47Bang, JS, Oh da, H, Choi, HM, et al. (2009) Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1beta-stimulated fibroblast-like synoviocytes and in rat arthritis models. Arthritis Res Ther 11, R49.
48Srinivasan, K (2007) Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr 47, 735–748.
49Durgaprasad, S, Pai, CG, Vasanthkumar, JFA, et al. (2005) A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122, 315–318.
50Anand, P, Kunnumakkara, AB, Newman, RA, et al. (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4, 807–818.
51Sharma, RA, Steward, WP & Gescher, AJ (2007) Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 595, 453–470.